Vikram Lamba

Advanced Medical Optics, Inc. manufactures intraocular lens and optical medical devices for eye disorders. Its products includes intraocular lenses, laser vision correction systems, phacoemulsification systems, viscoelastics, microkeratomes and related products used in cataract and refractive surgery. It develops sovereign system, which is equipped with WhiteStar software that uses ultrasound power to dissolve dense cataracts that can develop in the eye, Amadeus microkeratome, a device used during LASIK procedures and Verisyse phakic IOL for treatment of moderate to severe myopia. It was founded in 1976 Santa Ana, CA.

GeneOhm Sciences, Inc. develops molecular diagnostic products. It offers methicillin-resistant staphylococcus aureus (MRSA) Assay an in vitro diagnostic test for the direct detection of MRSA from a nasal specimen. The company was founded on 2001 and is headquartered in Franklin Lakes, NJ.

ZP Opco, Inc. operates as a biopharmaceutical company that develops transdermal delivery technology for therapeutic indications. The company was founded by Peter E. Daddona and Frank D. Stonebanks in 2006 and is headquartered in Fremont, CA.

J.E.M. Capital, Inc. is a a shell company, which engages in the identification of a privately held operating company which desires to become a publicly held entity by merging with the firm through a reverse merger or acquisition. The company was founded on September 14, 2011 and is headquartered in Hong Kong.

Burmah Castrol Plc is an international manufacturer and marketer of specialised lubricants and chemicals, operating in over 60 countries worldwide. The group operates mainly under the Castrol brand name in lubricant

Castrol, Ltd. produces and offers lubricant solutions for cars and bikes. Its products include engine and gear oils, greases, ancillaries, automatic transmission fluid and brake fluids, and motorcycle care products. The company was founded in 1899 and is headquartered in Swindon, UK.

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

ImmPACT Bio USA, Inc. operates as a cell therapy company. The firm develops potent and selective engineered T-cells for the treatment of solid tumors. The company is headquartered in Camarillo, CA.